Skip to main content

Find Clinical Trials

Home
Conditions
Familial Hemophagocytic Lymphohistiocytosis Type 3 (FHL 3)

Clinical trial condition

Familial Hemophagocytic Lymphohistiocytosis Type 3 (FHL 3)

Explore clinical trials studying Familial Hemophagocytic Lymphohistiocytosis Type 3 (FHL 3). Study availability and eligibility vary by location and protocol.

1 public trial 0 recruiting studies

Refine in advanced search Browse all conditions

Familial Hemophagocytic Lymphohistiocytosis Type 3 (FHL 3) trial results

Not Yet Recruiting

Safety and Efficacy of Gene Therapy of FHL Type 3 Caused by Mutations in the Human UNC13D Gene by Transplantation of a Single Dose of Autologous CD34+ Cells Transduced ex Vivo With the UNC13D LV Vector Expressing the UNC13D cDNA

NCT06736080

Conditions: Familial Hemophagocytic Lymphohistiocytosis Type 3 (FHL 3)
Locations: Department of Biotherapy, Hopital Necker Enfants Malades Paris, France

View Trial Details